Ulster says 'NO'; explosion, resistance and tolerance: Nitric oxide and the actions of organic nitrates

Ulster Medical Journal

Volumn 67, Issue 2, 1998, Pages 79-90

  Johnston, G D ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYL NITRATE; EXPLOSIVE; GLYCERYL TRINITRATE; NITRIC OXIDE; ORGANIC NITRATE;

ACUTE HEART INFARCTION; ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG MECHANISM; DRUG TOLERANCE; ENDOTHELIUM LESION; EXPLOSION; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; NEURALGIA; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; TOOTH PAIN;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; HUMANS; NITRATES; NITRIC OXIDE; VASODILATOR AGENTS;

EID: 0032424652     PISSN: 00416193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Brunton T L. On the use of nitrite of amyl in angina pectoris. Lancet 1867; 2: 97-8.
2. Murrell W. Nitro-glycerine as a remedy for angina pectoris. Lancet 1879; 1: 80-1.
3. Furchgott R F, Zawadzki J V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
4. Palmer R M J et al. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
5. McVeigh G E, Brennan G M, Johnston G D et al. Impaired endothelium dependent and independent vasodilation in patients with type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 1992; 35: 771-6.
6. McVeigh G, Brennan G, Hayes R, Johnston G D. Primary nitrate tolerance in diabetes mellitus. Diabetologia 1994; 37: 115-7.
7. Varriale P, David W J, Chryssos B E. Haemodynamic resistance to intravenous nitroglycerin in severe congestive heart failure and restored response after diuresis. Am J Cardiol 1991; 68: 1400-2.
8. Katz S D, Schwarz M, Yuen J, LeJemtel H. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure: role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 1993; 88: 55-61.
9. Keith R A, Burkman A M, Sokoloski T D, Fertel R H. Vascular tolerance to nitroglycerin and cyclic GMP generation in rat aortic smooth muscle. J Pharmacol Exp Ther 1982; 221: 525-31.
10. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997-1000.
11. Palmer R J M, Ashton D S, Moncada S. Vascular endothelial cells synthesise nitric oxide from L-arginine. Nature 1988; 333: 664-6.
12. Guerra R, Brotherton A F A, Goodwin P J et al. Mechanisms of abnormal endothelium-dependent vascular relaxation in atherosclerosis: implications for altered autocrine and paracrine functions of EDRF. Blood Vessels 1989; 26: 300-14.
13. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5.
14. Strano A, Davi G, Patrono C. In vivo platelet activation in diabetes mellitus. Semin Thromb Hemost 1991; 17: 422-5.
15. Block K D, Wolfram J R, Brown D M et al. Three members of the nitric oxide synthase II gene family (NOS2A, NOS2B and NOS2C) co-localise to human chromosome 17. Genomics 1995; 27: 526-30.
16. Marsden P A, Heng H H Q Scherer S W et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478-88.
17. Nadoud S, Bonnardeaux A, Lathrop M et al. Gene structure, polymorphism and mapping of the human endothelial nitric oxide synthase gene. Biochem Biophys Res Common 1994; 198: 1027-33.
18. Taguchi J, Abe J, Okazaki H et al. L-arginine inhibits neointimal formation following balloon injury. Life Sci 1993; 53: 387-92.
19. Barnes P J. Nitric oxide and airways. Eur Respir J 1993; 6: 163-5.
20. Sprague R, Thiemermann C, Vane J R. Endogenous endothelium derived relaxing factor opposes hypoxic pulmonary vasoconstriction and supports blood flow to hypoxic alveoli in anaesthetised rabbits. Proc Acad Sci USA 1992; 89: 8711-5.
21. Snyder S H. Nitric oxide: first in a new class of neurotransmitters? Science 1992; 257: 494-6.
22. Hibbs J B (Jr). Synthesis of nitric oxide from L-arginine: a recently discovered pathway induced by cytokines with antitumour and antimicrobial activity. Res Immunol 1991; 142: 565-9.
23. Desai K M, Sessa W C, Vane J R. Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature 1991; 351: 477-9.
24. Schmidt H H W, Warner T D, Ishi K et al. Insulin secretion from pancreatic ,ß cells caused by L-arginine-derived nitrogen oxides. Science 1992; 255: 721-3.
25. Burnett A L, Lowenstein C J, Bredt D S et al. Nitric oxide: a physiologic mediator of penile erection. Science 1992; 257: 401-3.
26. Liew F Y, Li Y, Severn A et al. A possible novel pathway of regulation by murine T helper type-2 cells (Th2) of a Th1 cell activity via the modulation of the induction of nitric oxide synthase in macrophages. Eur J Immunol 1991; 21: 2489-94.
27. Vallance P, Moncada S. Role of endogenous nitric oxide in septic shock. New Horiz 1993; 1: 77-87.
28. Oyama Y, Kawaski H, Hattori Y, Kanno M. Attenuation of endothelium-dependent relaxation in aorta from diabetic rats. Eur J Pharmacol 1986; 132: 75-8.
29. Plane F, Bruckdorfer K R, Kerr P et al. Oxidative modification of low-density lipoproteins and the inhibition of relaxations mediated by endothelium derived nitric oxide in rabbit aorta. Br J Pharmacol 1992; 105: 216-22.
30. Luscher T F, Vanhoutte P M. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986; 8: 344-8.
31. Luscher T F, Noll G. Endothelium dysfunction in the coronary circulation. J Cardiovas Pharmacol 1994; 24: Suppl 3, S16-26
32. Mayhan W G, Simmons L K, Sharpe G M. Mechanism of impaired responses of cerebral arterioles during diabetes mellitus. Am J Physiol 1991; 260: H319-26.
33. Chakravarthy U, Stitt A W, McNally J et al. Nitric oxide synthase activity and expression in retinal capillary endothelial cells and pericytes. Curr Eye Res 1995; 14: 285-94.
34. Taylor P D, McCarthy A L, Thomas C R et al. Endothelium-dependent relaxation and noradrenaline sensitivity in mesenteric resistance arteries of streptozotocin-induced diabetic rats. Br J Pharmacol 1992; 107: 393-9.
35. Saenz de Tejada I, Goldstein I, Azadroi K et al. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989; 320: 1025-30.
36. Zeiher A M, Krause T, Schachinger V et al. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischaemia. Circulation 1995; 91: 2345-52.
37. Simionescu M, Simionescu N. Functions of the endothelial cell surface. Ann Rev Physiol 1986; 48: 279-304.
38. Springer T A. The sensation and regulation of interactions with the extracellular environment: the cell biology of lymphocyte adhesion receptors. Ann Rev Cell Biol 1990; 6: 359-402.
39. DiCorleto P E. Cellular mechanisms of atherogenesis. Am J Hypertens 1993; 6: Suppl, 314S-8.
40. Schaberg T, Lauer C, Lode H et al. Increased number of alveolar macrophages expressing adhesion molecules of the leukocyte adhesion molecule family in smoking subjects: association with cell-binding ability and superoxide anion production. Am Rev Respir Dis 1992; 146: 1287-93.
41. Gilcrease M Z, Hoover R L. Examination of monocyte adherence to endothelium under hyperglycaemic conditions. Am J Path 1991; 139: 1089-97.
42. Gordon D, Reidy M A, Benditt E P et al. Cell proliferation in human coronary arteries. Proc Nat Acad Sci USA 1990; 87: 4600-4.
43. Capron L, Jarnet J, Kazandjian S, Housset E. Growth-promoting effects of diabetes and insulin on arteries: an in vivo study of rat aorta. Diabetes 1986; 35: 973-8.
44. Steiner G. Diabetes and atherosclerosis: an overview. Diabetes 1981; 30: Suppl 2: 1-7.
45. Uitto J, Perejda A J, Grant G A et al. Glycosylation of human glomerular basement membrane collagen: increased content of hexose in ketoamine linkage and unaltered hydroxyly sine-O-glycosides in patients with diabetes. Connect Tissue Res 1982; 10: 287-96.
46. Bucala R, Tracey K J, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-8.
47. Taylor P D, Poston L. The effect of hyperglycaemia on function of rat isolated mesenteric resistance artery. Br J Pharmacol 1994; 113: 801-8.
48. Tesfamariam B, Palacino J J, Weisbrod R M et al. Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J Cardiovasc Pharmacol 1993; 21: 205-11.
49. Wohaieb S A, Godin D V. Alterations in the free radical tissue-defence mechanisms in streptozocin-induced diabetes in the rat: effects of insulin treatment. Diabetes 1987; 36: 1014-18.
50. Tesfamariam B, Cohen R A. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992; 263: H321-6.
51. Gilligan D M, Guetta V, Panza J A et al. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994; 90: 35-41.
52. Millar B C, McGrath L T, Hillocks M J et al. The cytotoxic effect of low density lipoprotein from non-insulin-dependent diabetics. Proceedings of the Scientific Conference on the Functional and Structural Aspects of the Vascular Wall. Circulation Research 1995; 29-30.
53. Stout R W. Insulin as a mitogenic factor: role in the pathogenesis of cardiovascular disease. Am J Med 1991; 90 (Suppl 2A): 62S-5.
54. Panza J A, Quyyumi A A, Brushe J E (Jr) et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-7.
55. Sawicki P T, Heinemann L, Starke A, Berger M. Hyperinsulinaemia is not linked with blood pressure elevation in patients with insulinoma. Diabetologia 1992; 35: 649-52.
56. Flavahan N A. Atherosclerosis or lipoprotein-induced endothelial dysfunction: potential mechanism underlying reduction in EDRF/nitric oxide activity. Circulation 1992; 85: 1927-38.
57. Henderson A H. Endothelium in control. Br Heart J 1991; 65: 116-25.
58. Calver A, Collier J, Vallence P. Nitric oxide and cardiovascular control. Exp Physiol 1993; 78: 303-26.
59. Wright C L, Rees D D, Moncada S. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 1992; 26: 48-57.
60. Thiemermann C, Szabó C, Mitchell J A et al. Vascular hyperactivity to vasoconstrictor agents and haemodynamic decompensation in haemorrhagic shock is mediated by nitric oxide. Proc Nat Acad Sci USA 1993; 90: 267-71.
61. Bruce I N, Harris C M, Nugent A et al. Enhanced endothelium-dependent vasodilator responses in patients with systemic vasculitis. Scand J Rheumatol 1997; 26: 318-24.
62. Drexler H, Hayoz D, Münzel T et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69: 1596-1601.
63. Maguire S, Nugent A, McGurk C et al. Abnormal vascular responses in chronic cardiac failure are both endothelium dependent and independent. Heart
64. Vanderwinden J M, Mailleux P, Schiffmann S N et al. Nitric oxide synthase activity in infantile hypertrophic pyloric stenosis. N Engl J Med 1992; 327: 511-5.
65. Rajfer J, Aronson W J, Bush P A et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90-4.
66. De Belder A J, MacAllister R, Radomski MW et al. Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc Res 1994; 28: 691-4.
67. Higenbottam T. Inhaled nitric oxide: a magic bullet? Q J Med 1993; 86: 555-8.
68. Rossaint R, Falke K J, López F et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1992; 328: 399-405.
69. Pepke-Zaba J, Higenbottam T W, Dinh-Xuan A T et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173-4.
70. Mancini G B J, Henry G C, Macaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-65.
71. Nakamura M, Fanakoshi T, Arakawa N et al. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. J Am Coll Cardiol 1994; 24: 1321-7.
72. Drexler H, Zeiher A M, Meinzer K et al. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338: 1546-50.
73. Egashira K, Hirooka Y, Kuga T et al. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 1996; 94: 130-4.
74. Drexler H, Fischell T A, Pinto F J et al. Effect of L-arginine on coronary endothelial function in cardiac transplant recipients: relation to vessel wall morphology. Circulation 1994; 89: 1615-23.
75. Bhagat K. Clinical promise of nitric oxide. Br Cardiol 1997; 4: 238-241.
76. Gross S S, Levi R. Tetrahydrobiopterin synthesis: an absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle. J Bio Chem 1992; 267: 25722-9.
77. Bates J N, Baker M T et al. Nitric oxide generation from nitroprusside by vascular tissue: evidence that reduction of nitroprusside anion and cyanide loss are required. Biochem Pharmacol 1991; 42: Suppl 55, S157-65.
78. Feelisch M, Noack E A. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987; 139: 19-30.
79. Thadani U, Hamilton S F, Olson E et al. Transdermal nitroglycerin patches in angina pectoris: dose titration, duration of effect, and rapid tolerance. Ann Int Med 1986; 105: 485-92.
80. Packer M, Medina N, Yushak M et al. Hemodynamic factors limiting the response to transdermal nitroglycerin in severe chronic congestive heart failure. Am J Cardiol 1986; 57: 260-7.
81. Elright G E. The effects of nitroglycerin on those engaged in its manufacture. JAMA 1914: 62: 201-2.
82. Lang R L, Reid M S, Tresch D D et al. Non atheromatous ischaemic heart disease following withdrawal from chronic industrial nitroglycerin exposure. Circulation 1972; 46: 666-78.
83. Ignarro L J, Lippton H, Edwards J C et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of s-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981; 218: 739-49.
84. Fung H L, Chong S, Kowaluk K et al. Mechanisms for the pharmacologic interaction of organic nitrate with thiols: existence of an extracellular pathway for the reversal of nitrate vascular tolerance by N acetylcysteine. J Pharmacol Exp Ther 1988; 245: 524-30.
85. Packer M, Lee W H, Kessler P D et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987; 317: 799-804.
86. Cowan J C, Bourke J P, Reid D S et al. Prevention of tolerance to nitroglycerin patches by overnight removal. Am J Cardiol 1987; 60: 271-5.
87. Parker J O, Farrell B, Lahey K A et al. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med 1987; 316: 1440-4.
88. Sharpe N, Coxon R, Webster et al. Hemodynamic effects of intermittent transdermal nitroglycerin in chronic congestive heart failure. Am J Cardiol 1987; 59: 895-9.
89. Elkayam U, Jamison M, Roth A et al. Oral isosorbide dinitrate in chronic heart failure: tolerance development of qid vs tid regimen. J Am Coll Cardiol 1989; Suppl 13A: 178A.
90. Parker J O, Vankoughnett K A, Farrel B. Comparison of buccal nitroglycerin and oral isosorbide dinitrate for nitrate tolerance in stable angina pectoris. Am J Cardiol 1985: 56: 724-8.
91. De Mots H, Glasser S P. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989; 13: 786-93.
92. Abrams J. Nitrate tolerance and dependence. Am Heart J 1980; 99: 113-23.
93. Jugdutt B I. Intravenous nitroglycerin unloading in acute myocardial infarction. Am J Cardiol 1991; 68: 52D-63D.
94. Jugdutt B I. Nikates in myocardial infarction. Cardiovasc Drugs Ther 1994; 8: 635-46.
95. Jugdutt B I, Warnica J W. Tolerance with low dose intravenous nitroglycerin therapy in acute myocardial infarction. Am J Cardiol 1989; 64: 581-7.
96. Jugdutt B I, Sussex B A, Warnica J W et al. Persistent reduction in left ventricular asynergy in patients with acute myocardial infarction by intravenous infusion of nitroglycerin. Circulation 1983; 68: 1264-73.
97. Hunt J V, Smith C C T, Wolff S P. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1990; 39: 1420-4.
98. Collier A, Wilson R, Bradley H et al. Free radical activity in type 2 diabetes. Diabetic Med 1990; 7: 27-30.
99. Nugent A G, McGurk C, Hayes J R et al. Vascular responses to glyceryl trinitrate and sodium nitroprusside in type II diabetes mellitus. Br J Clin Pharmacol 1996; 41: 443P-4.